Top

Published in:

01-10-2021 | Mesothelioma | Original Article

Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis

Authors: Nazim Benzerdjeb, Peggy Dartigues, Vahan Kepenekian, Séverine Valmary-Degano, Eliane Mery, Gerlinde Avérous, Anne Chevallier, Marie-Hélène Laverriere, Irène Villa, Olivier Harou, Françoise Galateau Sallé, Laurent Villeneuve, Olivier Glehen, Sylvie Isaac, Juliette Hommell-Fontaine, Frédéric Bibeau, on behalf of the RENAPE Network

Published in: Virchows Archiv | Issue 4/2021

Abstract

Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. The relationship between a strong adaptive immune response and a better prognosis in malignant solid tumors is widely known. Due to the low incidence of epithelioid malignant peritoneal mesothelioma (EMPM), very little is known about their immune micro-environment. We encountered several cases of tertiary lymphoid structures in EMPM in a previous study and aimed to investigate in the same series the prevalence, clinicopathological features, and the prognostic impact associated with tertiary lymphoid structures in EMPM (TLS-EMPM). Cases of EMPM, from 1995 to 2018, were retrieved from 7 French institutions from the RENAPE Network. The predictions in terms of overall survival (OS) and progression-free survival (PFS) of TLS-EMPM were analyzed. We report 52 cases of TLS-EMPM among a series of 138 cases of EMPM. TLS-EMPM was significantly associated with neoadjuvant chemotherapy, and was not a prognostic indicator for OS (p = 0.652) and PFS (p = 0.804) in our series. TLS is a component of the host immune response to EMPM significantly associated with neoadjuvant chemotherapy, but was not a predictor of prognosis for overall and progression-free survivals in this series. These findings provide another possible etiology for tertiary lymphoid structures.

Glehen O. Mésothéliome péritonéal malin. In: Orphanet. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=168811&lng=FR

Husain A, Colby T, Ordóñez N et al (2018) Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 142:89–108. https://doi.org/10.5858/arpa.2017-0124-RACrossRefPubMed

Yan T, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242. https://doi.org/10.1200/JCO.2009.23.9640CrossRefPubMed

Fridman W, Pagès F, Sautès-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298–306. https://doi.org/10.1038/nrc3245CrossRefPubMed

Maoz A, Dennis M, Greenson J (2019) The Crohn’s-like lymphoid reaction to colorectal cancer-tertiary lymphoid structures with immunologic and potentially therapeutic relevance in colorectal cancer. Front Immunol 10:1884. https://doi.org/10.3389/fimmu.2019.01884CrossRefPubMedPubMedCentral

Väyrynen J, Sajanti S, Klintrup K et al (2014) Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J Cancer 134:2126–2135. https://doi.org/10.1002/ijc.28533CrossRefPubMed

Villeneuve L, Passot G, Glehen O et al (2017) The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J Rare Dis 12:37. https://doi.org/10.1186/s13023-017-0571-yCrossRefPubMedPubMedCentral

Jacquet P, Sugarbaker P (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374. https://doi.org/10.1007/978-1-4613-1247-5_23CrossRefPubMed

Graham D, Appelman H (1990) Crohn’s-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol 3:332–335PubMed

10.

Ueno H, Hashiguchi Y, Shimazaki H et al (2013) Objective criteria for crohn-like lymphoid reaction in colorectal cancer. Am J Clin Pathol 139:434–441. https://doi.org/10.1309/AJCPWHUEFTGBWKE4CrossRefPubMed

11.

Villeneuve L, Isaac S, Glehen O et al (2014) The RENAPE Network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the Network and Role of the Pathologists. Ann Pathol 34:4–8. https://doi.org/10.1016/j.annpat.2014.01.008CrossRefPubMed

12.

Rosen L, Karrison T, Ananthanarayanan V et al (2018) Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol 31:598–606. https://doi.org/10.1038/modpathol.2017.170CrossRefPubMed

13.

Kadota K, Suzuki K, Colovos C et al (2012) A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma. Mod Pathol 25:260–271. https://doi.org/10.1038/modpathol.2011.146CrossRefPubMed

14.

Nicholson A, Sauter J, Nowak A et al (2020) EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. J Thorac Oncol 29:29–49. https://doi.org/10.1016/j.jtho.2019.08.2506CrossRef

15.

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013; Available from: http://www.r-project.org/

16.

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/bmt.2012.244CrossRefPubMed

17.

Baker P, Clement P, Young R (2005) Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol 123:724–737. https://doi.org/10.1309/2h0n-vrer-pp2l-jduaCrossRefPubMed

18.

Rivera E, Coffey J, Walsh D, Ehrenpreis E (2019) The mesentery, systemic inflammation, and Crohn’s disease. Inflamm Bowel Dis 25:226–234. https://doi.org/10.1093/ibd/izy201CrossRefPubMed

19.

Butnor K, Pavlisko E, Sporn T, Roggli V (2017) Malignant peritoneal mesothelioma and Crohn disease. J Clin Pathol 70:228–232. https://doi.org/10.1136/jclinpath-2016-203945CrossRefPubMed

20.

Hato S, Khong A, de Vries I, Lesterhuis W (2014) Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res 20:2831–2037. https://doi.org/10.1158/1078-0432CrossRefPubMed

21.

Deraco M, Baratti D, Hutanu I et al (2013) The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20:1093–1100. https://doi.org/10.1245/s10434-012-2845-xCrossRefPubMed

22.

Kepenekian V, Elias D, Passot G et al (2016) Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. Eur J Cancer 65:69–79. https://doi.org/10.1016/j.ejca.2016.06.002CrossRefPubMed

23.

Chu G, van Zandwijk N, Rasko J (2019) The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy. Front Oncol 9:1366. https://doi.org/10.3389/fonc.2019.01366CrossRefPubMedPubMedCentral

24.

Fuchs T, Chou A, Sioson L et al (2020) Stromal tumour-infiltrating lymphocytes (TILs) assessed using the ITWG system do not predict overall survival in a cohort of 337 cases of mesothelioma. Histopathology 76:1095–1101. https://doi.org/10.1111/his.14106CrossRefPubMed

25.

Vanbervliet-Defrance B, Delaunay T, Daunizeau T et al (2020) Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. Cancer Lett 472:29–39. https://doi.org/10.1016/j.canlet.2019.12.016CrossRefPubMed

Title: Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis
Authors: Nazim Benzerdjeb
Peggy Dartigues
Vahan Kepenekian
Séverine Valmary-Degano
Eliane Mery
Gerlinde Avérous
Anne Chevallier
Marie-Hélène Laverriere
Irène Villa
Olivier Harou
Françoise Galateau Sallé
Laurent Villeneuve
Olivier Glehen
Sylvie Isaac
Juliette Hommell-Fontaine
Frédéric Bibeau
on behalf of the RENAPE Network
Publication date: 01-10-2021
Publisher: Springer Berlin Heidelberg
Keywords: Mesothelioma
Cytostatic Therapy
Published in: Virchows Archiv / Issue 4/2021
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-021-03099-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Micronodular thymic carcinoma with lymphoid hyperplasia: relevance of immunohistochemistry with a small panel of antibodies for diagnosis—a RYTHMIC study

Correction to: Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2‑positive breast cancer?

Correction to: Keratin 7 expression in hepatic cholestatic diseases

Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis

Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?

Clear cell tumor with melanocytic differentiation and MITF-CREM translocation: a novel entity similar to clear cell sarcoma